Pharmacogenetics of asthma controller treatment

E. B. Mougey, C. Chen, K. G. Tantisira, K. V. Blake, S. P. Peters, Robert A Wise, S. T. Weiss, J. J. Lima

Research output: Contribution to journalArticle

Abstract

The interpatient variability in response to asthma controllers is significant and associates with pharmacogenomic variability. The goal of the present study was to identify novel variants that associate with response to common asthma controllers: fluticasone, combination of fluticasone + salmeterol and montelukast with single nucleotide polymorphisms (SNPs) in β2-adrenergic receptor, corticosteroid and leukotriene pathway candidate genes. Participants in a large clinical trial of step-down strategies volunteered for this pharmacogenetic study. A total of 169 SNPs in 26 candidate genes were genotyped in 189 Caucasian participants with asthma who took either fluticasone (100 μg bid), fluticasone propionate (100 μg) + salmeterol (50 μg) (FP/Salm) or montelukast (5 or 10 mg) each night for 16 weeks. Primary outcomes were the slopes of plots of Asthma Control Questionnaire (ACQ) scores versus time following randomization; and the percent change in percent predicted FEV1 (ΔFEV1%pred) from enrollment to the end of the study. Associations between SNPs and outcomes were analyzed using general linear models. False discovery rate and Bonferroni corrections were used to correct for multiple comparisons. In all, 16 SNPs in seven genes were significantly associated with outcomes. For FP/Salm, three SNPs in CHRM2 associated with ACQ slope (P=2.8 × 10-5), and rs1461496 in HSPA8 associated with ΔFEV1%pred. For fluticasone, five SNPs in CRHR1 (P=1.9 × 10 -4), and three SNPs in COL2A1 associated with ACQ slope and ΔFEV1%pred, respectively. For montelukast, four SNPs in CHRM2 associated with ΔFEV1%pred and predicted an opposite effect compared with fluticasone (P=9 × 10-3). The present study indentified several novel SNPs that associate with response to common asthma controllers, and support further pharmacogenomic study and the use of genetic variants to personalize asthma treatment.

Original languageEnglish (US)
Pages (from-to)242-250
Number of pages9
JournalPharmacogenomics Journal
Volume13
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Pharmacogenetics
Single Nucleotide Polymorphism
montelukast
Asthma
Genes
Leukotrienes
Random Allocation
Adrenergic Receptors
Linear Models
Adrenal Cortex Hormones
Fluticasone
Clinical Trials
prednylidene

Keywords

  • Asthma
  • Caucasians
  • controller
  • genes
  • pharmacogenetics
  • polymorphisms

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Mougey, E. B., Chen, C., Tantisira, K. G., Blake, K. V., Peters, S. P., Wise, R. A., ... Lima, J. J. (2013). Pharmacogenetics of asthma controller treatment. Pharmacogenomics Journal, 13(3), 242-250. https://doi.org/10.1038/tpj.2012.5

Pharmacogenetics of asthma controller treatment. / Mougey, E. B.; Chen, C.; Tantisira, K. G.; Blake, K. V.; Peters, S. P.; Wise, Robert A; Weiss, S. T.; Lima, J. J.

In: Pharmacogenomics Journal, Vol. 13, No. 3, 06.2013, p. 242-250.

Research output: Contribution to journalArticle

Mougey, EB, Chen, C, Tantisira, KG, Blake, KV, Peters, SP, Wise, RA, Weiss, ST & Lima, JJ 2013, 'Pharmacogenetics of asthma controller treatment', Pharmacogenomics Journal, vol. 13, no. 3, pp. 242-250. https://doi.org/10.1038/tpj.2012.5
Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, Wise RA et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics Journal. 2013 Jun;13(3):242-250. https://doi.org/10.1038/tpj.2012.5
Mougey, E. B. ; Chen, C. ; Tantisira, K. G. ; Blake, K. V. ; Peters, S. P. ; Wise, Robert A ; Weiss, S. T. ; Lima, J. J. / Pharmacogenetics of asthma controller treatment. In: Pharmacogenomics Journal. 2013 ; Vol. 13, No. 3. pp. 242-250.
@article{2c5b9ae051984b3988e4419f049504a7,
title = "Pharmacogenetics of asthma controller treatment",
abstract = "The interpatient variability in response to asthma controllers is significant and associates with pharmacogenomic variability. The goal of the present study was to identify novel variants that associate with response to common asthma controllers: fluticasone, combination of fluticasone + salmeterol and montelukast with single nucleotide polymorphisms (SNPs) in β2-adrenergic receptor, corticosteroid and leukotriene pathway candidate genes. Participants in a large clinical trial of step-down strategies volunteered for this pharmacogenetic study. A total of 169 SNPs in 26 candidate genes were genotyped in 189 Caucasian participants with asthma who took either fluticasone (100 μg bid), fluticasone propionate (100 μg) + salmeterol (50 μg) (FP/Salm) or montelukast (5 or 10 mg) each night for 16 weeks. Primary outcomes were the slopes of plots of Asthma Control Questionnaire (ACQ) scores versus time following randomization; and the percent change in percent predicted FEV1 (ΔFEV1{\%}pred) from enrollment to the end of the study. Associations between SNPs and outcomes were analyzed using general linear models. False discovery rate and Bonferroni corrections were used to correct for multiple comparisons. In all, 16 SNPs in seven genes were significantly associated with outcomes. For FP/Salm, three SNPs in CHRM2 associated with ACQ slope (P=2.8 × 10-5), and rs1461496 in HSPA8 associated with ΔFEV1{\%}pred. For fluticasone, five SNPs in CRHR1 (P=1.9 × 10 -4), and three SNPs in COL2A1 associated with ACQ slope and ΔFEV1{\%}pred, respectively. For montelukast, four SNPs in CHRM2 associated with ΔFEV1{\%}pred and predicted an opposite effect compared with fluticasone (P=9 × 10-3). The present study indentified several novel SNPs that associate with response to common asthma controllers, and support further pharmacogenomic study and the use of genetic variants to personalize asthma treatment.",
keywords = "Asthma, Caucasians, controller, genes, pharmacogenetics, polymorphisms",
author = "Mougey, {E. B.} and C. Chen and Tantisira, {K. G.} and Blake, {K. V.} and Peters, {S. P.} and Wise, {Robert A} and Weiss, {S. T.} and Lima, {J. J.}",
year = "2013",
month = "6",
doi = "10.1038/tpj.2012.5",
language = "English (US)",
volume = "13",
pages = "242--250",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics of asthma controller treatment

AU - Mougey, E. B.

AU - Chen, C.

AU - Tantisira, K. G.

AU - Blake, K. V.

AU - Peters, S. P.

AU - Wise, Robert A

AU - Weiss, S. T.

AU - Lima, J. J.

PY - 2013/6

Y1 - 2013/6

N2 - The interpatient variability in response to asthma controllers is significant and associates with pharmacogenomic variability. The goal of the present study was to identify novel variants that associate with response to common asthma controllers: fluticasone, combination of fluticasone + salmeterol and montelukast with single nucleotide polymorphisms (SNPs) in β2-adrenergic receptor, corticosteroid and leukotriene pathway candidate genes. Participants in a large clinical trial of step-down strategies volunteered for this pharmacogenetic study. A total of 169 SNPs in 26 candidate genes were genotyped in 189 Caucasian participants with asthma who took either fluticasone (100 μg bid), fluticasone propionate (100 μg) + salmeterol (50 μg) (FP/Salm) or montelukast (5 or 10 mg) each night for 16 weeks. Primary outcomes were the slopes of plots of Asthma Control Questionnaire (ACQ) scores versus time following randomization; and the percent change in percent predicted FEV1 (ΔFEV1%pred) from enrollment to the end of the study. Associations between SNPs and outcomes were analyzed using general linear models. False discovery rate and Bonferroni corrections were used to correct for multiple comparisons. In all, 16 SNPs in seven genes were significantly associated with outcomes. For FP/Salm, three SNPs in CHRM2 associated with ACQ slope (P=2.8 × 10-5), and rs1461496 in HSPA8 associated with ΔFEV1%pred. For fluticasone, five SNPs in CRHR1 (P=1.9 × 10 -4), and three SNPs in COL2A1 associated with ACQ slope and ΔFEV1%pred, respectively. For montelukast, four SNPs in CHRM2 associated with ΔFEV1%pred and predicted an opposite effect compared with fluticasone (P=9 × 10-3). The present study indentified several novel SNPs that associate with response to common asthma controllers, and support further pharmacogenomic study and the use of genetic variants to personalize asthma treatment.

AB - The interpatient variability in response to asthma controllers is significant and associates with pharmacogenomic variability. The goal of the present study was to identify novel variants that associate with response to common asthma controllers: fluticasone, combination of fluticasone + salmeterol and montelukast with single nucleotide polymorphisms (SNPs) in β2-adrenergic receptor, corticosteroid and leukotriene pathway candidate genes. Participants in a large clinical trial of step-down strategies volunteered for this pharmacogenetic study. A total of 169 SNPs in 26 candidate genes were genotyped in 189 Caucasian participants with asthma who took either fluticasone (100 μg bid), fluticasone propionate (100 μg) + salmeterol (50 μg) (FP/Salm) or montelukast (5 or 10 mg) each night for 16 weeks. Primary outcomes were the slopes of plots of Asthma Control Questionnaire (ACQ) scores versus time following randomization; and the percent change in percent predicted FEV1 (ΔFEV1%pred) from enrollment to the end of the study. Associations between SNPs and outcomes were analyzed using general linear models. False discovery rate and Bonferroni corrections were used to correct for multiple comparisons. In all, 16 SNPs in seven genes were significantly associated with outcomes. For FP/Salm, three SNPs in CHRM2 associated with ACQ slope (P=2.8 × 10-5), and rs1461496 in HSPA8 associated with ΔFEV1%pred. For fluticasone, five SNPs in CRHR1 (P=1.9 × 10 -4), and three SNPs in COL2A1 associated with ACQ slope and ΔFEV1%pred, respectively. For montelukast, four SNPs in CHRM2 associated with ΔFEV1%pred and predicted an opposite effect compared with fluticasone (P=9 × 10-3). The present study indentified several novel SNPs that associate with response to common asthma controllers, and support further pharmacogenomic study and the use of genetic variants to personalize asthma treatment.

KW - Asthma

KW - Caucasians

KW - controller

KW - genes

KW - pharmacogenetics

KW - polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84878242736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878242736&partnerID=8YFLogxK

U2 - 10.1038/tpj.2012.5

DO - 10.1038/tpj.2012.5

M3 - Article

C2 - 22370858

AN - SCOPUS:84878242736

VL - 13

SP - 242

EP - 250

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -